New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:18 EDTTKMR, MONTekmira receives $14.5M milestone payment from Monsanto
Tekmira Pharmaceuticals (TKMR) confirmed that it has received $14.5M of the net $16.5M in near term payments as outlined in the terms of an option agreement signed with Monsanto (MON), which supports the application of Tekmira's proprietary delivery technology and related intellectual property for use in agriculture. The agreement follows Monsanto's initial testing of Tekmira's proprietary delivery technology and the demonstration of initial positive results from use of that technology in the field of agriculture. The companies' agreement and research collaboration is focused on the development of new innovative biological solutions for farmers, which have the potential to provide new options for sustainable pest, virus and weed control.
News For TKMR;MON From The Last 14 Days
Check below for free stories on TKMR;MON the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2014
06:13 EDTTKMRTekmira to collaborate with international consortium researching Ebola
Subscribe for More Information
September 22, 2014
13:02 EDTTKMRTekmira surges on FDA authorization of TKM-Ebola for emergency use
Subscribe for More Information
12:57 EDTTKMRTekmira up 20% following FDA authorization of TKM-Ebola for emergency use
09:16 EDTTKMRTekmira establishes regulatory framework for emergency use of TKM-Ebola
Subscribe for More Information
September 18, 2014
12:44 EDTMONMonsanto optimistic about Intacta sales in Brazil
Subscribe for More Information
12:33 EDTMONMonsanto reiterates target of doubling EPS between now and 2019
Subscribe for More Information
10:00 EDTMONOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:02 EDTMONMonsanto upgraded at Stifel
Subscribe for More Information
06:10 EDTMONMonsanto upgraded to Buy from Hold at Stifel
September 17, 2014
15:02 EDTTKMRCongressman questions why FDA hasn't moved on Ebola drug, The Hill says
Republican Congressman Michael Burgess said he was "bewildered" as to why the FDA continues to have a hold on Tekmira's TKS-Ebloa drug, a treatment for Ebola, according to The Hill. However, Democratic Congresswoman Betty McCollum warned against using Africa as a "testing ground" for drugs that haven't been property screened, the website noted. Reference Link
September 15, 2014
07:14 EDTMONMonsanto Intacta-traited soy seed largely sold out, says Piper Jaffray
Subscribe for More Information
September 11, 2014
12:03 EDTMONUSDA raises U.S. corn yield forecast to record
In its monthly World Agricultural Supply and Demand Estimates, or WASDE, report, the U.S. Department of Agriculture's corn yield forecast is raised 4.3 bushels per acre to a record 171.7 bushels. Corn production for 2014/15 is forecast 363 million bushels higher at a record 14,395 million bushels. Total 2014/15 corn usage is projected at 13,605 million bushels, up 170 million from last month. Although a record, usage is expected up just 5 million bushels from 2013/14 as export prospects remain constrained by large foreign carryin stocks, the USDA wrote. Publicly traded companies in the agriculture space include Agrium (AGU), Andersons (ANDE), Archer Daniels (ADM), Bunge (BG), CF Industries (CF), Compass Minerals (CMP), DuPont (DD), Intrepid Potash (IPI), Monsanto (MON), Mosaic (MOS), Potash (POT) and Syngenta (SYT).
10:20 EDTTKMRNebraska Medical Center not naming Ebola drug, The Street reports
Nebraska Medical Center is not releasing the name of the experimental Ebola drug being given to Dr. Rick Sacra, The Street's Adam Feuerstein reports, citing an emailed response from the hospital. Traders are speculating Tekmira (TKMR) is the manufacturer of the drug, Feuerstein points out. Sarepta (SRPT) disclosed that it is not involved in the treatment of Sacra, added Feuerstein. Shares of Tekmira are up 3% to $19.65 in morning trading. Reference Link
September 10, 2014
11:29 EDTMONMonsanto's Intacta remains on track, says Credit Suisse
Credit Suisse said Monsanto Intacta demand remains strong and check's indicate it is fully on track to meet the high end of its 10m-12M acre guidance for Brasil.
11:20 EDTMONMonsanto: Intacta demand 'in line,' pre-pays above expectation, Bloomberg says
Subscribe for More Information
10:43 EDTMONMonsanto shares defended at JPMorgan
Subscribe for More Information
09:39 EDTMONMonsanto view downgraded to Negative from Mixed at OTR Global
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use